Lilly’s Eczema Contender Promising, But Needs Head-To-Head Data To Dent Dupixent Dominance
Also Vital For Partners Almirall
Executive Summary
Topline results suggest lebrikizumab could outshine Sanofi’s Dupixent on safety and itch reduction in atopic eczema, but a direct comparison study is likely required to drive the message home.
You may also be interested in...
Musical Chairs: Lilly Leadership Changes Underscore Confidence In Donanemab Accelerated Approval
Oncology leader Anne White will oversee neuroscience and pain, while Bio-Medicines head Ilya Yuffa will take over for retiring Lilly International president; Loxo CEO will oversee entire oncology business.
Rinvoq Shows Strong UC Efficacy, But Will JAK Ghosts Haunt It?
Safety appears balanced between the drug and placebo arms in upadacitinib’s third Phase III trial in ulcerative colitis, but there were low numbers of MACE and there are lingering safety concerns about the JAK class overall.
Precision Picks New CEO To Tackle Gene Editing’s Commercial Challenges
Precision is looking ahead to market access challenges for its off-the-shelf CAR-T and in vivo gene-editing therapies.